{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:58:25Z","timestamp":1791305905627,"version":"4.3.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,2,1]]},"DOI":"10.1093\/humrep\/deh612","type":"journal-article","created":{"date-parts":[[2004,11,12]],"date-time":"2004-11-12T01:14:49Z","timestamp":1100222089000},"page":"563-568","source":"Crossref","is-referenced-by-count":67,"title":["Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens"],"prefix":"10.1093","volume":"20","author":[{"given":"Huib A.A.M.","family":"van Vliet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Frolich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Christella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.G.D.","family":"Thomassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carine J.M.","family":"Doggen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frits R.","family":"Rosendaal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rosing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frans M.","family":"Helmerhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2005,2]]},"reference":[{"key":"key\n\t\t\t\t20171012083745_R1","doi-asserted-by":"crossref","unstructured":"Anderson DC (1974) Sex-hormone-binding globulin. Clin Endocrinol (Oxf)3, 69\u201396.","DOI":"10.1111\/j.1365-2265.1974.tb03298.x"},{"key":"key\n\t\t\t\t20171012083745_R2","doi-asserted-by":"crossref","unstructured":"Barkfeldt J, Virkkunen A and Dieben T (2001) The effects of two progestogen-only pills containing either desogestrel (75\u2009microg\/day) or levonorgestrel (30\u2009microg\/day) on lipid metabolism. Contraception64, 295\u2013299.","DOI":"10.1016\/S0010-7824(01)00269-4"},{"key":"key\n\t\t\t\t20171012083745_R3","doi-asserted-by":"crossref","unstructured":"Crona N, Silfverstolpe G and Samsioe G (1984) Changes in serum apo-lipoprotein AI and sex-hormone-binding globulin levels after treatment with two different progestins administered alone and in combination with ethinyl estradiol. Contraception29, 261\u2013270.","DOI":"10.1016\/S0010-7824(84)80006-2"},{"key":"key\n\t\t\t\t20171012083745_R4","doi-asserted-by":"crossref","unstructured":"El Makhzangy MN, Wynn V and Lawrence DM (1979) Sex hormone binding globulin capacity as an index of oestrogenicity or androgenicity in women on oral contraceptive steroids. Clin Endocrinol (Oxf)10, 39\u201345.","DOI":"10.1111\/j.1365-2265.1979.tb03031.x"},{"key":"key\n\t\t\t\t20171012083745_R5","doi-asserted-by":"crossref","unstructured":"Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV and Lundin FE (1991) Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol133, 32\u201337.","DOI":"10.1093\/oxfordjournals.aje.a115799"},{"key":"key\n\t\t\t\t20171012083745_R6","doi-asserted-by":"crossref","unstructured":"Kemmeren JM, Algra A and Grobbee DE (2001) Third generation oral contraceptives and risk of venous thrombosis: meta-analysis. Br Med J323, 131\u2013134.","DOI":"10.1136\/bmj.323.7305.131"},{"key":"key\n\t\t\t\t20171012083745_R7","doi-asserted-by":"crossref","unstructured":"Kemmeren JM, Algra A, Meijers JC, Tans G, Bouma BN, Curvers J, Rosing J and Grobbee DE (2004) Effect of second- and third-generation oral contraceptives on the protein C system in the absence or presence of the factor V Leiden mutation: a randomized trial. Blood103, 927\u2013933.","DOI":"10.1182\/blood-2003-04-1285"},{"key":"key\n\t\t\t\t20171012083745_R8","doi-asserted-by":"crossref","unstructured":"Knopp RH, Broyles FE, Cheung M, Moore K, Marcovina S and Chandler WL (2001) Comparison of the lipoprotein, carbohydrate, and hemostatic effects of phasic oral contraceptives containing desogestrel or levonorgestrel. Contraception63, 1\u201311.","DOI":"10.1016\/S0010-7824(00)00196-7"},{"key":"key\n\t\t\t\t20171012083745_R9","doi-asserted-by":"crossref","unstructured":"Odlind V, Milsom I, Persson I and Victor A (2002) Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand81, 482\u2013490.","DOI":"10.1034\/j.1600-0412.2002.810603.x"},{"key":"key\n\t\t\t\t20171012083745_R10","doi-asserted-by":"crossref","unstructured":"Rosendaal FR, Van Hylckama Vlieg A, Tanis BC and Helmerhorst FM (2003) Estrogens, progestogens and thrombosis. J Thromb Haemost1, 1371\u20131380.","DOI":"10.1046\/j.1538-7836.2003.00264.x"},{"key":"key\n\t\t\t\t20171012083745_R11","doi-asserted-by":"crossref","unstructured":"Rosing J, Tans G, Nicolaes GA, Thomassen MC, Van Oerle R, van der Ploeg PM, Heijnen P, Hamulyak K and Hemker HC (1997) Oral contraceptives and venous thrombosis: different sensitivities to activated protein C in women using second- and third-generation oral contraceptives. Br J Haematol97, 233\u2013238.","DOI":"10.1046\/j.1365-2141.1997.192707.x"},{"key":"key\n\t\t\t\t20171012083745_R12","doi-asserted-by":"crossref","unstructured":"Rosing J, Middeldorp S, Curvers J, Thomassen MC, Nicolaes GA, Meijers JC, Bouma BN, B\u00fcller HR, Prins MH and Tans G (1999) Low-dose oral contraceptives and acquired resistance to activated protein C: a randomised cross-over study. Lancet354, 2036\u20132040.","DOI":"10.1016\/S0140-6736(99)06092-4"},{"key":"key\n\t\t\t\t20171012083745_R13","doi-asserted-by":"crossref","unstructured":"Sheldon T (2002) Dutch GPs warned against new contraceptive pill. Br Med J324, 869.","DOI":"10.1136\/bmj.324.7342.869"},{"key":"key\n\t\t\t\t20171012083745_R14","doi-asserted-by":"crossref","unstructured":"Tans G, van Hylckama Vlieg A, Thomassen MC, Curvers J, Bertina RM, Rosing J and Rosendaal FR (2003) Activated protein C resistance determined with a thrombin generation-based test predicts for venous thrombosis in men and women. Br J Haematol122, 465\u2013470.","DOI":"10.1046\/j.1365-2141.2003.04443.x"},{"key":"key\n\t\t\t\t20171012083745_R15","unstructured":"van Hylckama Vlieg A (2003) Causes of venous thrombosis: procoagulant factors and oral contraceptives [dissertation]. Leiden University, Leiden."},{"key":"key\n\t\t\t\t20171012083745_R16","doi-asserted-by":"crossref","unstructured":"van Kammen E, Thijssen JH, Rademaker B and Schwarz F (1975) The influence of hormonal contraceptives on sex hormone binding globulin (SHBG) capacity. Contraception11, 53\u201359.","DOI":"10.1016\/0010-7824(75)90050-5"},{"key":"key\n\t\t\t\t20171012083745_R17","doi-asserted-by":"crossref","unstructured":"van Rooijen M, Silveira A, Hamsten A and Bremme K (2004) Sex hormone\u2013binding globulin\u2014a surrogate marker for the prothrombotic effects of combined oral contraceptives. Am J Obstet Gynecol190, 332\u2013337.","DOI":"10.1016\/S0002-9378(03)00950-5"},{"key":"key\n\t\t\t\t20171012083745_R18","doi-asserted-by":"crossref","unstructured":"Vandenbroucke JP, Rosing J, Bloemenkamp KW, Middeldorp S, Helmerhorst FM, Bouma BN and Rosendaal FR (2001) Oral contraceptives and the risk of venous thrombosis. N Engl J Med344, 1527\u20131535.","DOI":"10.1056\/NEJM200105173442007"},{"key":"key\n\t\t\t\t20171012083745_R19","doi-asserted-by":"crossref","unstructured":"van der Vange N, Blankenstein MA, Kloosterboer HJ, Haspels AA and Thijssen JH (1990) Effects of seven low-dose combined oral contraceptives on sex hormone binding globulin, corticosteroid binding globulin, total and free testosterone. Contraception41, 345\u2013352.","DOI":"10.1016\/0010-7824(90)90034-S"},{"key":"key\n\t\t\t\t20171012083745_R20","doi-asserted-by":"crossref","unstructured":"van Vliet HA, Winkel TA, Noort I, Rosing J and Rosendaal FR (2004) Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate. J Thromb Haemost, in press.","DOI":"10.1111\/j.1538-7836.2004.00983.x"},{"key":"key\n\t\t\t\t20171012083745_R21","doi-asserted-by":"crossref","unstructured":"Vasilakis-Scaramozza C and Jick H (2001) Risk of venous thromboembolism with cyproterone or levonorgestrel contraceptives. Lancet358, 1427\u20131429.","DOI":"10.1016\/S0140-6736(01)06522-9"},{"key":"key\n\t\t\t\t20171012083745_R22","unstructured":"World Health Organization (1996) Improving Access to Quality Care in Family Planning. Medical Eligibility Criteria for Contraceptive Use. World Health Organization, Geneva."}],"container-title":["Human Reproduction"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/humrep\/article-pdf\/20\/2\/563\/1649803\/deh612.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,4]],"date-time":"2020-04-04T00:52:38Z","timestamp":1585961558000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/humrep\/article\/20\/2\/563\/603271\/Association-between-sex-hormonebinding-globulin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,2,1]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2005,2]]},"published-print":{"date-parts":[[2005,2,1]]}},"URL":"https:\/\/doi.org\/10.1093\/humrep\/deh612","relation":{},"ISSN":["1460-2350","0268-1161"],"issn-type":[{"value":"1460-2350","type":"electronic"},{"value":"0268-1161","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,2]]},"published":{"date-parts":[[2005,2,1]]}}}